Mvasi (Bevacizumab)

Bevacizumab, the active ingredient in Mvasi, is a monoclonal antibody presented as a solution for injection for intravenous use. It targets multiple solid tumours by inhibiting angiogenesis and is indicated for adult patients with several advanced cancers. GNH USA supplies Mvasi as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres and pharmacies worldwide.

Mvasi is an anti‑angiogenic monoclonal antibody used in oncology to block tumour blood‑vessel growth. - Metastatic colorectal cancer: used with chemotherapy to slow disease progression and improve survival. - Non‑small cell lung cancer: combined with standard regimens to enhance response rates. - Glioblastoma: administered to limit tumour vascularisation and extend progression‑free survival. - Renal cell carcinoma: added to targeted therapy to reduce tumour growth. - Ovarian cancer: incorporated in first‑line treatment to increase overall response. - Cervical cancer: combined with chemoradiation to improve disease control.

Common Side Effects: - Hypertension: elevated blood pressure requiring monitoring and management. - Proteinuria: presence of protein in urine, often mild and reversible. - Fatigue: generalised tiredness that may affect daily activities. - Infusion‑related reactions: flushing, chills, or mild rash during administration.

Serious or Rare Side Effects: - Arterial thromboembolic events: risk of heart attack or stroke. - Gastrointestinal perforation: rare but potentially life‑threatening bowel rupture. - Severe hemorrhage: uncontrolled bleeding, especially in patients on anticoagulants. - Anaphylaxis: acute allergic reaction requiring immediate medical intervention.

Mvasi requires careful clinical monitoring due to its potent anti‑angiogenic activity. - Pregnancy: safety not established; avoid unless potential benefit outweighs risk. - Bleeding risk: assess coagulation status and avoid in patients with active hemorrhage. - Wound healing: postpone elective surgery until drug clearance is confirmed. - Hypertension: monitor blood pressure regularly and treat elevations promptly. - Infusion: administer under medical supervision with emergency equipment available. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Bevacizumab may interact with several drug classes, requiring vigilance. Major Interactions (Avoid): - Concurrent anticoagulants: increased risk of severe bleeding. - Combination with other anti‑angiogenic agents: additive toxicity and vascular complications. - Live vaccines: heightened risk of infection due to impaired angiogenesis. Moderate Interactions (Monitor Closely): - Chemotherapy agents causing myelosuppression: monitor blood counts closely. - NSAIDs: may exacerbate bleeding tendencies.